Q4 FY2025 · Press release
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration · March 24, 2026 · 2 pages
Read Ocugen, Inc.'s results firsthand
Preview this press release
Create a free account to start reading
Full documents are included with Professional